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highlighted the need to monitor individual patient 
deformation during the treatment course. This application of 
SPC showed that EWMA charts can efficiently detect small 
shifts early on in the treatment, which would enable a timely 
decision for plan adaptation if necessary. 
Conclusions: SPC is a very effective tool for reviewing and 
monitoring the accuracy of patient positioning. 
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Experimental studies on the retreatment tolerance of 
previously irradiated tissues have generally been performed 
in the 1980’s and 90’s, and were mostly limited in scope. 
Generally, the retreatment tolerance of different tissues and 
organs differ for early and late responding tissues. 
Early responding tissues are characterized by rapid 
proliferation and a clearly defined stem cell compartment 
(epidermis, mucosal lining of GI-tract) with the timing of 
response related to the turnover times of stem cells.  Except 
after very severe early reactions these tissues show a 
complete restauration of tolerance. 
Late tissue reactions in slowly or non-proliferating tissues 
show a much more limited long term recovery which is also 
dependent on the dose of the initial treatment. An example 
of such a tissue is the lung, contrasting with the kidney that 
does not show any recovery at all.  
A paradoxical exception is the central nervous system, which 
based on its proliferation characteristics is not expected to 
show any significant recovery. However, extensive studies in 
several institutions have shown that the spinal cord shows 
almost complete recovery when the initial dose is 
approximately 50-75% of full tolerance.   
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Purpose: Despite aggressive multimodality treatment 
protocols used in first-line treatment, a significant proportion 
of patients with different cancer develop locoregional 
recurrences in previously irradiated area, typically during the 
first years of follow-up. Compared to salvage external-beam 
radiation therapy the salvage interstitial brachytherapy offers 
clearly better possibility to give high doses without inevitably 
leading to high complication rates.  
Methods and results: The author analyses and review the 
role of salvage brachytherapy in previously irradiated 
patients with breast cancer, prostate cancer, head-and-neck 
malignancies, Gyn tumors, cancer of anorectal region and 
other tumors.  
An overview of selected results of modern image-guided 
salvage brachytherapy will be given. The analysis makes 
evident, that re-irradiation with doses in the range of 55-60 
Gy (after previous irradiation up to doses of 60-70 Gy) 
represents very narrow tightrope walk between realistic 
tumor control probability and an unacceptable incidence of 
serious side effects. However, a reasonable number of these 
patients, if selected carefully, may have a chance for long-
term disease control. The observed local control rates of 
salvage brachytherapy for previously irradiated recurrent 
head and neck cancer vary very widely between 16% and 86% 
after 2 to 5 years, for previously irradiated recurrent 
prostate cancer between 30% and 90%, for previously 
irradiated recurrent breast cancer about 95%, et cetera. The 
salvage external beam radiation therapy is in these 
indications mostly not possible and compared with the results 
of salvage surgery the salvage brachytherapy seems to offer 
lower toxicities in all indications.  
Conclusion: Salvage interstitial brachytherapy in selected 
patients with locoregional recurrences in previously 
irradiated area is for a whole range of tumors proven, safe 
and effective treatment method with very good long-term 
data and with minimal toxicity.  
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Purpose: Re-irradiation of the recurrences in the areas of 
head and neck (h/n) and upper respiratory tract should 
always be considered as a risky treatment. These cancers 
quite often need to be radiate the second time because of 
their relapse and clinical advancement in the primary 
examination. High dose rate brachytherapy (HDR-BT) is very 
useful in short time tumor dose delivering when external 
beam radiotherapy (EBRT) is not possible to depot once more 
after previous treatment failure. Pulsed dose rate 
brachytherapy (PDR-BT) is safe but longer method of salvages 
and according to differences in recovery times allows better 
sparing healthy tissue during second radiation treatment. The 
aim of this work was to analyze the results and complications 
rates of another radiation treatment patients with recurrent 
tumors in head and neck and upper respiratory tract. 
Material and methods: 47 patients with h/n and 22 with 
larynx/trachea (l/t) recurrent cancers were enrolled  to the 
study. The mean time of the recurrence after diagnosing of 
the disease and first treatment was 9,7 months. 50 patients 
were treated by the HDR brachytherapy (5 doses of 4 Gy) and 
19 by PDR-BT with total dose ranged between 20-40 Gy (0,8 
Gy per pulse) with one or two stage treatments (respectively 
9 and 4 doses). HDR-BT and PDR-BT were performed with a 
remote afterloading microSelectron unit (192Ir source) after 
planning procedure (Oncentra system). Mean age of patients 
undergoing observation was 50,1 years. 
In three l/t patients, BT procedures were performed in 
combination with simultaneous chemotherapy. In 16 patients 
cytoreduction of the tumor preceded interstitial, surgical 
catheter placement. Local control, survival rates and 
tolerance of the treatment were discussed. 
Results: The remission after 1,3,6 months after treatment 
and early complication were assessed. In 15% patients 
complete remission (CR), in 65,9% partial remission (PR) and 
10,6 % no response for brachytherapy (NR) were stated; in 
the other (8,5%) patients there were progression (P) of the 
tumor. Percentages of remission after 3 and 6 months were: 
CR – 10,6 % and 6,4%, PR – 53,2% and 36,2%, NR and P – 36,2% 
and 57,4%, respectively. For the l/t group complete and 
partial remissions in 6 months treatment time were achieved 
in 20% patients, survival rate 24 months after BT were 
estimated for 22%. Progression of the disease was noted in 
60% of cases.  The most common side effect was superficial 
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necrosis – 74,5% in 6 months observation time for each: HDR-
BT and PDR-BT method in h/n.  Serious late side-effects were 
seen in two patients (9%) - l/t and PDR-BT group.  
Conclusions: 1. HDR and PDR both had similar percentages of 
side effects. 2. Early complications due to the total radiation 
dose are frequent and needs to be treated by intensive 
pharmacology. 3. HDR or PDR are effective tools in tumor 
recurrence radiation treatment, when surgical procedure is 
impossible and using another EBRT schedule very dangerous 
for the patient.  4. Future studies should aim to determine 
the maximum tolerated dose and appropriate patient 
selection.   
Key words: head and neck cancer, HDR brachytherapy, PDR,  
recurrence, salvage treatment.   
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Purpose/Objective: Irresectable locoregional recurrent 
breast cancer in previously irradiated area is a life 
threatening disease and optimal treatment is still a matter of 
debate. Re-irradiation combined with hyperthermia 
(reRT+HT) is a valid treatment option. Four hundred and 
fourteen patients were treated with reRT+HT in the AMC 
(n=301) and the BVI (n=113), from January 1982 up to 
January 2006. We calculated response rates and local control 
(LC). Prognostic factors for tumor control were analysed in a 
multivariable analysis, with special emphasis on tumor size.  
Materials and Methods:  All patients previously received 
radiation, overlapping the current reRT field, to a median 
dose of 50Gy with or without boost. Median interval between 
initial treatment and reRT+HT was 54 months (range, 3-469). 
Most patients (80%) received one or more courses of systemic 
therapy in the past. 
The median age was 57 years at start of reRT+HT. The 
estimated tumour size was >10cm in 48% of patients (range 
0.2 – 26 cm). Distant metastases (DM) were present in 36% of 
patients and 74% had experienced previous recurrence 
episodes (range, 1-13). ReRT consisted typically of 8x4Gy, 
twice a week (AMC) or 12x3Gy, four times a week (BVI). 
Superficial hyperthermia was added once (ACM)/twice (BVI) a 
week using 434MHz Contact Flexible Microstrip Applicators. 
Aim temperature was 41-43°C for one hour. Twenty-two 
percent of patients received additional chemotherapy and 
30% additional hormone therapy. 
Results: Overall clinical response rate was 86% (58% cCR + 
28% cPR). Median follow-up (FU) 17 months. Median overall 
survival was 17 months. The 3-year LC rate was 25%. Tumor 
size, time interval to recurrence, the number of previous 
recurrent episodes, and prescence of DM were significant 
prognostic factors for LC. For patients with isolated 
locoregional recurrences ≤ 5 cm the 3-year LC rate was 47%.  
(Table.1).  
 
 
 
Conclusions: Re-irradiation combined with hyperthermia for 
locoregional recurrence after previous irradiation results in 
high response rates of 86%, despite resistance to previous 
treatments. Overall long-term LC control was 25%, but up to 
47% in smaller tumors (< 5cm.). Tumor size, and absence of 
DM were positive prognostic factors for LC duration and 
overall survival. 
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Purpose/Objective: The outcome of current treatment of 
locally-advanced and recurrent head and neck carcinoma 
(HNC) in patients treated with radiotherapy alone is 
disappointing. The combination treatment of radiotherapy 
(RT) and cisplatin or cetuximab improves survival. Increased 
toxicity and comorbidity prohibiting combined treatment 
with cisplatin or cetuximab warrant the need for another 
radiosensitizer. Stimulated by several randomised studies 
demonstrating the radio-sensitizing effect of hyperthermia, 
we developed the HYPERcollar for applying deep 
hyperthermia in the HNC region. Here, we report the early 
experience and toxicity of deep hyperthermia treatment 
combined with radiotherapy in a cohort of patients with 
advanced HNC. 
Materials and Methods: In total, 119 hyperthermia 
treatments given to 27 patients, treated with advanced HNC, 
were included in this analysis. Hyperthermia was applied for 
60 minutes, or later 75 minutes, depending on patients’ 
tolerance using the HYPERcollar, aimed at achieving 43°C in 
the target region. Treatment quality was monitored by 
patient specific hyperthermia pre-treatment planning 
combined with real-time invasive thermometry if possible, or 
pre-treatment planning alone. RT was given using either 
external beam irradiation (Cyberknife or IMRT) or interstitial 
irradiation. 
Results: Applying hyperthermia in the very well perfused 
head and neck region proved to be challenging and high 
power levels were required (median 543W). 13% of the 
hyperthermia treatments were not fully completed, mostly 
due to pain (5%), which we allocated to hyperthermia 
treatment and dyspnoea (2%) caused by sticky saliva, 
associated with irradiation. Mean hyperthermia treatment 
time was 94% of planned duration. No severe complications 
or enhanced thermal or mucosal toxicities were observed. 
Preferably, metal implants (>1cm) should be removed to 
minimize the risk of toxicity, and prevent any unpredictable 
resonances reducing the predictive value of treatment 
